Physician profile
Robert Barriger
NPI 1740448240
$1,272.38
in general payments reported to CMS, 2019-2025
27 companies · $578 in 2025
The $578 reported for 2025 was more than what 77% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.54 · 2022: $356 · 2023: $38.73 · 2024: $219 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $217.65 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $202.46 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $112.14 | 2022 | |
| Ethicon INC. | $81.54 | 2021 | |
| Janssen Biotech, INC. | $68.31 | 2022-2023 | Talvey |
| Takeda Pharmaceuticals U.S.A., INC. | $57.43 | 2022-2025 | Fruzaqla |
| Telix Pharmaceuticals | $51.80 | 2024 | Illuccix |
| Daiichi Sankyo INC. | $49.53 | 2022-2024 | Enhertu |
| Pfizer INC. | $47.63 | 2025 | |
| Amgen INC. | $42.25 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.32 | 2025 | |
| Pharmacosmos Therapeutics INC. | $33.37 | 2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $29.34 | 2025 | Libtayo |
| Tempus Ai, INC | $27.99 | 2025 | Xt Cdx |
| Janssen Scientific Affairs, LLC | $25.75 | 2024 | Darzalex |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $22.08 | 2024 | |
| Genmab U.S., INC. | $20.50 | 2025 | Tivdak |
| Seagen INC. | $17.30 | 2022 | |
| Boston Scientific Corporation | $16.97 | 2025 | Spaceoar Vue System - 10ml |
| Agios Pharmaceuticals, INC. | $15.85 | 2022 | |
| Lilly USA, LLC | $14.73 | 2022 | |
| Glaxosmithkline, LLC. | $14.47 | 2025 | Zejula |
| Adaptive Biotechnologies Corporation | $13.55 | 2025 | Clonoseq |
| Pharming Healthcare, INC. | $13.53 | 2022 | |
| Incyte Corporation | $13.19 | 2022 | |
| Taiho Oncology, INC. | $12.53 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $12.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barriger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.